To determine the sensitivity and reproducibility of the patient-specific hybrid-capture panels, primary tumor DNA samples from patients TB52 (TNBC), BCR486 (ER+), and BCR503 (HER2+) were serially diluted into unmatched buffy coat DNA; the same buffy coat DNA was used for all three dilutions. The gene discussed is ERBB2; the disease is neoplasm.